Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

MLA

Oliva, Esther N., et al. “Early Lenalidomide Treatment for Low and Intermediate-1 International Prognostic Scoring System Risk Myelodysplastic Syndromes with Del(5q) before Transfusion Dependence.” Cancer Medicine, vol. 4, no. 12, Dec. 2015, pp. 1789–97. EBSCOhost, https://doi.org/10.1002/cam4.523.

APA

Oliva, E. N., Lauseker, M., Aloe Spiriti, M. A., Poloni, A., Cortelezzi, A., Palumbo, G. A., Balleari, E., Sanpaolo, G., Volpe, A., Ricco, A., Ronco, F., Alati, C., D’Errigo, M. G., Santacaterina, I., Kündgen, A., Germing, U., & Latagliata, R. (2015). Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Medicine, 4(12), 1789–1797. https://doi.org/10.1002/cam4.523

Chicago

Oliva, Esther N., Michael Lauseker, Maria Antonietta Aloe Spiriti, Antonella Poloni, Agostino Cortelezzi, Giuseppe A. Palumbo, Enrico Balleari, et al. 2015. “Early Lenalidomide Treatment for Low and Intermediate-1 International Prognostic Scoring System Risk Myelodysplastic Syndromes with Del(5q) before Transfusion Dependence.” Cancer Medicine 4 (12): 1789–97. doi:10.1002/cam4.523.